Abstract P4-14-08: Apatinib combined with docetaxel and platinum as neoadjuvant treatment for triple-negative/HER2-positive breast cancer: A randomized, open-label, multicenter, phase 2 trial

Phase 2 Trial ◽

Multicenter Phase ◽

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00373-3 ◽

2015 ◽

Vol 16 (16) ◽

pp. 1700-1710 ◽

Cited By ~ 65

Author(s):

Javier Cortés ◽

Véronique Dieras ◽

Jungsil Ro ◽

Jérôme Barriere ◽

Thomas Bachelot ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Choice Of Treatment ◽

Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70475-9 ◽

2014 ◽

Vol 15 (13) ◽

pp. 1493-1502 ◽

Cited By ~ 76

Author(s):

Bruno Coudert ◽

Jean-Yves Pierga ◽

Marie-Ange Mouret-Reynier ◽

Kaldoun Kerrou ◽

Jean-Marc Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Fdg Pet ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Trial ◽

18F Fdg ◽

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(11)70336-9 ◽

2012 ◽

Vol 13 (1) ◽

pp. 25-32 ◽

Cited By ~ 1133

Author(s):

Luca Gianni ◽

Tadeusz Pienkowski ◽

Young-Hyuck Im ◽

Laslo Roman ◽

Ling-Ming Tseng ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Phase 2 ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

BMC Medicine ◽

10.1186/s12916-018-1233-1 ◽

2019 ◽

Vol 17 (1) ◽

Cited By ~ 5

Author(s):

Joaquín Gavilá ◽

Mafalda Oliveira ◽

Tomás Pascual ◽

Jose Perez-Garcia ◽

Xavier Gonzàlez ◽

...

Keyword(s):

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Molecular Heterogeneity ◽

Phase 2 ◽

Single Group ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Abstract PS13-12: Apatinib combined with taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, open-label, phase II trial

10.1158/1538-7445.sabcs20-ps13-12 ◽

2021 ◽

Author(s):

Yunjiang Liu ◽

Xiangmei Zhang ◽

Li Wang ◽

Miao Cao ◽

Shuo Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Her2 Positive ◽

Open Label ◽

Open Label Phase ◽

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study

Oncotarget ◽

10.18632/oncotarget.26286 ◽

2018 ◽

Vol 9 (86) ◽

pp. 35687-35704 ◽

Cited By ~ 18

Author(s):

Begoña Martin-Castillo ◽

Sonia Pernas ◽

Joan Dorca ◽

Isabel Álvarez ◽

Susana Martínez ◽

...

Keyword(s):

Breast Cancer ◽

Phase 2 ◽

Her2 Positive ◽

Phase 2 Trial ◽

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)00163-7 ◽

2016 ◽

Vol 17 (6) ◽

pp. 791-800 ◽

Cited By ~ 259

Author(s):

Luca Gianni ◽

Tadeusz Pienkowski ◽

Young-Hyuck Im ◽

Ling-Ming Tseng ◽

Mei-Ching Liu ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Randomised Trial ◽

Locally Advanced ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Open Label Phase ◽

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(12)70049-9 ◽

2012 ◽

Vol 13 (4) ◽

pp. 375-384 ◽

Cited By ~ 107

Author(s):

Jean-Yves Pierga ◽

Thierry Petit ◽

Thierry Delozier ◽

Jean-Marc Ferrero ◽

Mario Campone ◽

...

Keyword(s):

Breast Cancer ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Study ◽

Abstract P2-16-23: The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative breast cancer (TNBC)

10.1158/0008-5472.sabcs13-p2-16-23 ◽

2013 ◽

Cited By ~ 2

Author(s):

A Awada ◽

N Spector ◽

I El-Hariry ◽

AA Rodriguez ◽

JK Erban ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 2 ◽

Proof Of Concept ◽

First Line ◽

Her2 Positive ◽

Open Label ◽

Concept Study ◽

Multicenter Phase

Abstract 2703: Final results of a phase 2 trial using a novel, non-anthracycline neoadjuvant chemotherapy regimen in Her2-positive breast cancer

10.1158/1538-7445.am2012-2703 ◽

2012 ◽

Cited By ~ 2

Author(s):

Ruth M. O'Regan ◽

Sheryl Gabram ◽

Toncred Styblo ◽

Monica Rizzo ◽

William Wood ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Chemotherapy Regimen ◽

Phase 2 ◽

Her2 Positive ◽

Phase 2 Trial ◽